Clinical trial · Interventional
Tumor and Treatments Impact on Neurocognitive Functions and Quality of Life of Patients With OMS Grade II Glioma
Tumor and Treatments Impact on Neurocognitive Functions and Quality of Life of Patients With OMS Grade II Glioma: Multicentric Prospective Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Recruitment too low
Summary
Brief summary (as posted)
This is a multicenter prospective study:2 independant cohorts of patients with OMS grade II glioma will be followed during 5 years. * cohort A: patients in first-line treatment (surgery, radiotherapy or chemotherapy) * cohort B: patients with disease simple monitoring. The primary endpoint is to evaluate the impact of tumor and treatments on neurocognitive functions and quality of life, using validate and standard tests.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| OMS Grade II Glioma | Glioma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| neurocognitive tests | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- OMS grade II glioma
- description
- neurocognitive tests
- interventionNames
- Behavioral: neurocognitive tests
Primary outcomes (1)
- measure
- MoCA test
- timeFrame
- 36 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * OMS grade II glioma * signed informed consent * age \>=18 * IK \>=80% * ability to read, write and undertand French Exclusion Criteria: * glioma localized to brainstem * other neurologic or psychiatric disease * history of other malignancies, other than curatively treated in-situ carcinoma of the cervix or basal cell carcinoma of the skin, or any other curatively treated cancer with no sign of recurrence within 5 years prior to randomization * neuroleptic concomitant treatment * pregnant or lactating women
References
Publications (0)
Data not yet available